Peptide Therapy for Men: Mechanism, Evidence, Lab Protocols

Peptide Therapy in Men: Mechanism and Clinical Application

Men's Health Month is the perfect time to revisit what actually works in testosterone optimization and performance enhancement. Peptide therapy—specifically GH-releasing peptides (GRPs) and GH-releasing hormone (GHRH) analogs—has emerged as a legitimate alternative to exogenous growth hormone, with a mechanistic advantage: they stimulate endogenous GH secretion rather than suppressing the hypothalamic-pituitary-gonadal (HPG) axis.

Here's what the evidence shows, and what matters clinically.

How Peptides Interact With the GH Axis

The growth hormone secretory axis operates on a straightforward feedback loop: GHRH (growth hormone-releasing hormone) signals the anterior pituitary to release GH, which then stimulates hepatic IGF-1 production. Elevated IGF-1 feeds back negatively on GHRH.

Peptides like sermorelin (GHRH analog) and hexarelin (GH secretagogue) bypass downstream suppression by directly stimulating the pituitary or ghrelin receptor, respectively. The result: sustained endogenous GH production without the secondary hypogonadism seen with pharmaceutical GH replacement.

This distinction matters. Exogenous GH suppresses GnRH, tanking testosterone and fertility. Peptides don't.

What the Literature Actually Says

A 2022 meta-analysis in Frontiers in Endocrinology showed GHRH analogs increase lean mass and reduce fat mass comparably to GH, but with preservation of HPG axis function. Sermorelin studies demonstrate IGF-1 increases of 20–35% over baseline in hypogonadal men when dosed at 0.2 mg daily subcutaneous injection.

Hexarelin and ipamorelin (GH secretagogues) show similar efficacy with an additional benefit: enhanced cortisol suppression, making them valuable in high-stress populations.

But—and this is critical—peptide efficacy depends entirely on baseline pituitary responsiveness. A man with prior anabolic steroid use, primary hypogonadism, or pituitary insufficiency will not respond well to peptides. This is why baseline labs are non-negotiable.

Baseline Blood Testing: The Non-Negotiable Protocol

Before starting any peptide therapy, order:

• GH and IGF-1: Fasting, early morning (GH peaks 1–3 hours post-sleep). Normal IGF-1 in men: 100–300 ng/mL depending on age. Optimal for performance: 150–250 ng/mL.
• Full testosterone panel: Total T, free T, SHBG. Normal total T: 300–1000 ng/dL; optimal for symptom resolution and lean mass: 600–900 ng/dL.
• TSH, free T4, free T3: Peptides can amplify subclinical hypothyroidism. Optimal TSH: 1.0–2.0 mIU/L (not the lab reference of 0.4–4.0).
• Cortisol (24-hour urine or 4-point salivary): Elevated cortisol blunts GH response. Optimal 24-hr urine free cortisol: <50 µg/day.
• DHEA-S, estradiol: Peptides don't directly suppress these, but baseline values predict HPG axis health.
• Fasting glucose, HbA1c, lipid panel: Peptides improve insulin sensitivity; baseline establishes trajectory.

Synergistic Supplementation

Peptide efficacy amplifies with these compounds:

Magnesium Glycinate (400–500 mg daily): Cofactor for GHRH receptor signaling. Improves sleep quality, which is where endogenous GH secretion peaks.

Zinc (25–50 mg daily): Required for pituitary GH synthesis. Deficiency is common in older men and blunts response to peptides entirely.

Vitamin D3 + K2 (4,000 IU D3 + 180 µg K2 daily): D3 upregulates GH receptor expression; K2 activates osteocalcin, improving bone mineralization—critical in peptide users showing rapid lean mass gains.

Creatine Monohydrate (5 g daily): Synergizes with elevated IGF-1 for lean mass accrual. Improves intracellular phosphate buffering, enhancing muscle protein synthesis.

Omega-3 PUFA (2–3 g EPA+DHA daily): Reduces inflammation and improves sleep architecture—both amplify endogenous GH pulsatility.

NAC (600–1,200 mg daily): Restores glutathione, protecting against oxidative stress from rapid protein turnover during peptide therapy.

Collagen Peptides (10–20 g daily): Glycine + proline directly feed collagen synthesis. In men using peptides for joint health, this is additive.

Ashwagandha (300–600 mg daily of KSM-66): Lowers cortisol and improves sleep—both predictive of peptide response.

Practical Application and Monitoring

Sermorelin dosing: 0.2 mg subcutaneous injection daily, ideally pre-sleep. Retest IGF-1 at 8–12 weeks. If IGF-1 increases <15%, assess sleep quality, cortisol, and zinc status before increasing dose.

Hexarelin dosing: 100 µg subcutaneous injection 3× weekly. More potent cortisol suppression; useful in men with elevated baseline cortisol.

Monitoring cadence:

• 12 weeks: IGF-1, testosterone panel, HbA1c
• 6 months: Full repeat (TSH, DHEA-S, estradiol, lipids)
• Annually: DEXA scan if using peptides for bone or lean mass

The Bottom Line

Peptide therapy works—mechanistically and clinically—but only in men with intact pituitary function and optimized baseline health markers. The advantage over exogenous GH is preservation of the HPG axis. The requirement is intelligent baseline testing and lifestyle support: sleep, stress management, and strategic supplementation. Start with baseline labs. Use them to interpret your response. Adjust accordingly.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.